IPO Details
Bidding Dates
18 Jun 25 - 20 Jun 25
Lot Size
1200
Price Range ₹
91 - 96
Exchange Status
NSE
Total Equity
₹ 0.00Cr
IPO Doc
IPO Timeline
Listing
--
Offer start
18 Jun 2025
Offer end
20 Jun 2025
Allotment
23 Jun 2025
Refund initiation
24 Jun 2025
Demat transfer
24 Jun 2025
Listing
--
Offer start
18 Jun 2025
Offer end
20 Jun 2025
Allotment
23 Jun 2025
Refund initiation
24 Jun 2025
Demat transfer
24 Jun 2025
About Company
Incorporated in September 2020, Influx Healthtech Limited is a healthcare-focused contract development and manufacturing organization (CDMO) based in Thane, Maharashtra. The company operates three manufacturing facilities and offers a wide range of products, including tablets, capsules, softgels, gummies, oral dispersible films, Ayurvedic formulations, cosmetics, veterinary supplements, and homecare solutions. Influx provides end-to-end services—from product development to regulatory support—primarily serving nutraceutical and cosmetic companies. With a diversified product portfolio, stringent quality control practices, and an experienced management team, the company caters to a broad client base. As of June 11, 2025, it has 163 permanent employees.
Year Founded
28-09-2020
Promotor Details
Munir Abdul Ganee Chandniwala
Promoter Holdings Details
| Particular | Pre-IPO | Post-IPO |
|---|---|---|
| Percentage | 99.86 | 0 |
| Share Capital | 18123864 | 0 |
Project Details
- Funding Capital Expenditure for setting up of new manufacturing facility for Veterinary Food Divisio - 76.56cr
- Purchase of Machineries for Homecare and Cosmetic Division - 27.565cr
- Funding Capital Expenditure for setting up of new manufacturing facility for Nutraceutical Division - 193.126cr
Objectives
- Funding capital expenditure requirements for setting up of manufacturing facility for Nutraceutical Division.Funding capital expenditure requirements for setting up of manufacturing facility for Veterinary Food Division.Purchase of Machineries for Homecare and Cosmetic Division.General Corporate Purposes.
Highlights
- Wide and diversified product portfolio across healthcare, nutraceuticals, cosmetics, and veterinary segments.
- End-to-end CDMO services, including regulatory support, attract a broad client base.
- Operates three manufacturing facilities, ensuring adequate production capacity and scalability
- Strong quality assurance and control systems enhance product reliability and compliance.
- Experienced promoters and management team provide strategic direction and industry expertise.
Challenges
- Relatively new company (incorporated in 2020) with a limited operational track record.
- Heavy reliance on third-party clients makes revenue susceptible to demand fluctuations.
- Operates in highly competitive CDMO and nutraceutical markets with low entry barriers.
- Regulatory challenges across different product categories may increase compliance risk.
- Limited geographical presence, concentrated in Thane, may restrict market reach and expansion.
